SG Americas Securities LLC Purchases Shares of 13,189 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

SG Americas Securities LLC acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 13,189 shares of the specialty pharmaceutical company’s stock, valued at approximately $153,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KALV. Capital World Investors acquired a new stake in KalVista Pharmaceuticals in the 1st quarter valued at about $17,370,000. Great Point Partners LLC acquired a new stake in KalVista Pharmaceuticals in the second quarter valued at approximately $15,768,000. Entropy Technologies LP purchased a new position in KalVista Pharmaceuticals in the first quarter worth approximately $121,000. The Manufacturers Life Insurance Company grew its holdings in KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 3,314 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of KalVista Pharmaceuticals by 4.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after purchasing an additional 944 shares during the last quarter.

KalVista Pharmaceuticals Trading Up 0.5 %

KALV stock opened at $12.07 on Friday. The business has a 50 day simple moving average of $11.74 and a 200-day simple moving average of $12.11. The company has a market capitalization of $509.21 million, a P/E ratio of -3.55 and a beta of 0.89. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.21 and a twelve month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. Research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.35 EPS for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $170,722.15. Following the transaction, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the transaction, the chief executive officer now owns 242,527 shares in the company, valued at approximately $2,912,749.27. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,135 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the sale, the insider now directly owns 83,745 shares of the company’s stock, valued at $1,038,438. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,804 shares of company stock valued at $372,112 over the last three months. 12.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

KALV has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).